Table 4.
Adherence to baseline and follow-up studies, multivariable analysis, logistic regression models.
| Non adherence to baseline | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | TSH | Liver Enzymes | Electrolytes | CXR | ECG | ||||||||||
| OR | 95% CI | p -value | OR | 95% CI | p -value | OR | 95% CI | p -value | OR | 95% CI | p -value | OR | 95% CI | p -value | |
| Age | |||||||||||||||
| >80 | — | — | — | — | — | — | — | — | — | — | |||||
| 18–30 | 1.51 | 0.74, 3.00 | 0.2 | 1.70 | 0.81, 3.43 | 0.15 | 1.99 | 0.88, 4.20 | 0.083 | 1.07 | 0.50, 2.64 | 0.9 | 0.22 | 0.11, 0.42 | < 0.001 |
| 31–50 | 1.33 | 1.07, 1.64 | 0.010 | 1.70 | 1.35, 2.13 | < 0.001 | 2.04 | 1.57, 2.64 | < 0.001 | 0.68 | 0.55, 0.85 | < 0.001 | 0.53 | 0.42, 0.67 | < 0.001 |
| 51–70 | 1.12 | 1.03, 1.20 | 0.005 | 1.18 | 1.08, 1.28 | < 0.001 | 1.28 | 1.15, 1.42 | < 0.001 | 0.77 | 0.71, 0.83 | < 0.001 | 0.77 | 0.70, 0.84 | < 0.001 |
| 71–80 | 1.00 | 0.93, 1.07 | >0.9 | 0.99 | 0.91, 1.07 | 0.8 | 0.92 | 0.83, 1.02 | 0.12 | 0.82 | 0.76, 0.88 | < 0.001 | 0.79 | 0.72, 0.86 | < 0.001 |
| Gender | |||||||||||||||
| Female | — | — | — | — | — | — | — | — | — | — | |||||
| Male | 1.23 | 1.16, 1.31 | < 0.001 | 0.93 | 0.87, 1.00 | 0.043 | 0.94 | 0.86, 1.02 | 0.15 | 0.92 | 0.86, 0.98 | 0.012 | 0.88 | 0.81, 0.94 | < 0.001 |
| Dosage (mg) | |||||||||||||||
| 200–400 | — | — | — | — | — | — | — | — | — | — | |||||
| Above 400 | 0.83 | 0.70, 0.98 | 0.032 | 0.83 | 0.68, 1.00 | 0.055 | 0.81 | 0.63, 1.03 | 0.089 | 0.88 | 0.75, 1.04 | 0.13 | 0.86 | 0.72, 1.03 | 0.094 |
| Below 200 | 0.77 | 0.72, 0.83 | < 0.001 | 0.70 | 0.64, 0.76 | < 0.001 | 0.58 | 0.52, 0.65 | < 0.001 | 1.38 | 1.27, 1.51 | < 0.001 | 1.20 | 1.09, 1.32 | < 0.001 |
| Additional factors | |||||||||||||||
| Background thyrotoxicosis | 0.92 | 0.78, 1.07 | 0.3 | ||||||||||||
| Background hypothyroidism | 0.46 | 0.42, 0.49 | < 0.001 | ||||||||||||
| Primary care physician visits per year | 0.81 | 0.80, 0.82 | < 0.001 | 0.79 | 0.78, 0.80 | < 0.001 | 0.71 | 0.70, 0.73 | < 0.001 | 1.00 | 1.00, 1.00 | 0.8 | 1.00 | 0.99, 1.00 | 0.043 |
| Unspecified kidney failure | 0.75 | 0.67, 0.84 | < 0.001 | ||||||||||||
| Chronic hypertension | 0.66 | 0.60, 0.73 | < 0.001 | ||||||||||||
| COPD | 1.03 | 0.95, 1.12 | 0.4 | ||||||||||||
| Asthma | 0.94 | 0.85, 1.04 | 0.2 | ||||||||||||
| Characteristic | TSH | Liver enzymes | Electrolytes | ||||||||||||
| OR | 95% CI | p -value | OR | 95% CI | p -value | OR | 95% CI | p -value | |||||||
| Age | |||||||||||||||
| >80 | — | — | — | — | — | — | |||||||||
| 18–30 | 1.51 | 0.74, 3.00 | 0.2 | 1.70 | 0.81, 3.43 | 0.15 | 1.99 | 0.88, 4.20 | 0.083 | ||||||
| 31–50 | 1.33 | 1.07, 1.64 | 0.010 | 1.70 | 1.35, 2.13 | < 0.001 | 2.04 | 1.57, 2.64 | < 0.001 | ||||||
| 51–70 | 1.12 | 1.03, 1.20 | 0.005 | 1.18 | 1.08, 1.28 | < 0.001 | 1.28 | 1.15, 1.42 | < 0.001 | ||||||
| 71–80 | 1.00 | 0.93, 1.07 | >0.9 | 0.99 | 0.91, 1.07 | 0.8 | 0.92 | 0.83, 1.02 | 0.12 | ||||||
| Gender | |||||||||||||||
| Female | — | — | — | — | — | — | |||||||||
| Male | 1.23 | 1.16, 1.31 | < 0.001 | 0.93 | 0.87, 1.00 | 0.043 | 0.94 | 0.86, 1.02 | 0.15 | ||||||
| Dosage (mg) | |||||||||||||||
| 200–400 | — | — | — | — | — | — | |||||||||
| >400 | 0.83 | 0.70, 0.98 | 0.032 | 0.83 | 0.68, 1.00 | 0.055 | 0.81 | 0.63, 1.03 | 0.089 | ||||||
| < 200 | 0.77 | 0.72, 0.83 | < 0.001 | 0.70 | 0.64, 0.76 | < 0.001 | 0.58 | 0.52, 0.65 | < 0.001 | ||||||
| Additional factors | |||||||||||||||
| Background thyrotoxicosis | 0.92 | 0.78, 1.07 | 0.3 | ||||||||||||
| Background hypothyroidism | 0.46 | 0.42, 0.49 | < 0.001 | ||||||||||||
| Primary care physician visits per year | 0.81 | 0.80, 0.82 | < 0.001 | 0.79 | 0.78, 0.80 | < 0.001 | 0.71 | 0.70, 0.73 | < 0.001 | ||||||
| Unspecified kidney failure | 0.75 | 0.67, 0.84 | < 0.001 | ||||||||||||
| Chronic hypertension | 0.66 | 0.60, 0.73 | < 0.001 | ||||||||||||
OR, odds ratio; CI, confidence interval.